人源 CtBP 与底物 MTOB 复合物的晶体结构揭示了对抑制剂设计有用的活性位点特征。
Crystal structures of human CtBP in complex with substrate MTOB reveal active site features useful for inhibitor design.
机构信息
Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, MA 01605, USA.
Division of Hematology, Oncology, and Palliative Care and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.
出版信息
FEBS Lett. 2014 May 2;588(9):1743-8. doi: 10.1016/j.febslet.2014.03.026. Epub 2014 Mar 19.
Abstract
The oncogenic corepressors C-terminal Binding Protein (CtBP) 1 and 2 harbor regulatory d-isomer specific 2-hydroxyacid dehydrogenase (d2-HDH) domains. 4-Methylthio 2-oxobutyric acid (MTOB) exhibits substrate inhibition and can interfere with CtBP oncogenic activity in cell culture and mice. Crystal structures of human CtBP1 and CtBP2 in complex with MTOB and NAD(+) revealed two key features: a conserved tryptophan that likely contributes to substrate specificity and a hydrophilic cavity that links MTOB with an NAD(+) phosphate. Neither feature is present in other d2-HDH enzymes. These structures thus offer key opportunities for the development of highly selective anti-neoplastic CtBP inhibitors.
摘要
致癌核心抑制因子 C 端结合蛋白 (CtBP)1 和 2 含有调节 d-异构体特异性 2-羟基酸脱氢酶 (d2-HDH) 结构域。4-甲基硫代 2-氧代丁酸 (MTOB) 表现出底物抑制作用，并能在细胞培养和小鼠中干扰 CtBP 的致癌活性。与 MTOB 和 NAD(+) 结合的人 CtBP1 和 CtBP2 的晶体结构揭示了两个关键特征：一个保守的色氨酸，可能有助于底物特异性，以及一个亲水腔，将 MTOB 与 NAD(+) 磷酸盐连接起来。这些特征在其他 d2-HDH 酶中均不存在。因此，这些结构为开发高度选择性的抗肿瘤 CtBP 抑制剂提供了重要机会。
相似文献
1
Crystal structures of human CtBP in complex with substrate MTOB reveal active site features useful for inhibitor design.
FEBS Lett. 2014 May 2;588(9):1743-8. doi: 10.1016/j.febslet.2014.03.026. Epub 2014 Mar 19.
2
Structure-guided design of a high affinity inhibitor to human CtBP.
ACS Chem Biol. 2015 Apr 17;10(4):1118-27. doi: 10.1021/cb500820b. Epub 2015 Jan 30.
3
Assembly of human C-terminal binding protein (CtBP) into tetramers.
J Biol Chem. 2018 Jun 8;293(23):9101-9112. doi: 10.1074/jbc.RA118.002514. Epub 2018 Apr 26.
4
Therapeutic targeting of C-terminal binding protein in human cancer.
Cell Cycle. 2010 Sep 15;9(18):3740-50. doi: 10.4161/cc.9.18.12936. Epub 2010 Sep 8.
5
Design, synthesis, and biological evaluation of substrate-competitive inhibitors of C-terminal Binding Protein (CtBP).
Bioorg Med Chem. 2016 Jun 15;24(12):2707-15. doi: 10.1016/j.bmc.2016.04.037. Epub 2016 Apr 20.
6
NAD(H) phosphates mediate tetramer assembly of human C-terminal binding protein (CtBP).
J Biol Chem. 2021 Jan-Jun;296:100351. doi: 10.1016/j.jbc.2021.100351. Epub 2021 Jan 30.
7
Active-Site Tryptophan, the Target of Antineoplastic C-Terminal Binding Protein Inhibitors, Mediates Inhibitor Disruption of CtBP Oligomerization and Transcription Coregulatory Activities.
Mol Pharmacol. 2019 Jul;96(1):99-108. doi: 10.1124/mol.118.114363. Epub 2019 Apr 29.
8
Interaction of ZEB and histone deacetylase with the PLDLS-binding cleft region of monomeric C-terminal binding protein 2.
BMC Mol Biol. 2009 Sep 15;10:89. doi: 10.1186/1471-2199-10-89.
9
Transforming activity and therapeutic targeting of C-terminal-binding protein 2 in Apc-mutated neoplasia.
Oncogene. 2017 Aug 17;36(33):4810-4816. doi: 10.1038/onc.2017.106. Epub 2017 Apr 17.
10
Inhibition of C-terminal binding protein attenuates transcription factor 4 signaling to selectively target colon cancer stem cells.
Cell Cycle. 2014;13(22):3506-18. doi: 10.4161/15384101.2014.958407.
引用本文的文献
1
The specificity of CTBP dehydrogenase inhibitors MTOB and 4-Cl-HIPP.
MicroPubl Biol. 2025 Feb 3;2025. doi: 10.17912/micropub.biology.001415. eCollection 2025.
2
A new method for network bioinformatics identifies novel drug targets for mucinous ovarian carcinoma.
NAR Genom Bioinform. 2024 Aug 24;6(3):lqae096. doi: 10.1093/nargab/lqae096. eCollection 2024 Sep.
3
Oncogene drives acute myeloid leukemia via a targetable interaction with CTBP2.
Sci Adv. 2024 May 17;10(20):eadk9076. doi: 10.1126/sciadv.adk9076. Epub 2024 May 15.
4
Identification and characterization of a new potent inhibitor targeting CtBP1/BARS in melanoma cells.
J Exp Clin Cancer Res. 2024 May 6;43(1):137. doi: 10.1186/s13046-024-03044-5.
5
Metabolic modulation of CtBP dimeric status impacts the repression of DNA damage repair genes and the platinum sensitivity of ovarian cancer.
Int J Biol Sci. 2023 Apr 9;19(7):2081-2096. doi: 10.7150/ijbs.80952. eCollection 2023.
6
CtBP Neuroprotective Role in Toxin-Based Parkinson's Disease Models: From Expression Pattern to Dopaminergic Survival.
Mol Neurobiol. 2023 Aug;60(8):4246-4260. doi: 10.1007/s12035-023-03331-w. Epub 2023 Apr 15.
7
Transcriptomics and Metabolomics Integration Reveals Redox-Dependent Metabolic Rewiring in Breast Cancer Cells.
Cancers (Basel). 2021 Oct 9;13(20):5058. doi: 10.3390/cancers13205058.
8
The transrepression and transactivation roles of CtBPs in the pathogenesis of different diseases.
J Mol Med (Berl). 2021 Oct;99(10):1335-1347. doi: 10.1007/s00109-021-02107-w. Epub 2021 Jul 1.
9
Dimerization of PHGDH via the catalytic unit is essential for its enzymatic function.
J Biol Chem. 2021 Jan-Jun;296:100572. doi: 10.1016/j.jbc.2021.100572. Epub 2021 Mar 19.
10
NAD(H) phosphates mediate tetramer assembly of human C-terminal binding protein (CtBP).
J Biol Chem. 2021 Jan-Jun;296:100351. doi: 10.1016/j.jbc.2021.100351. Epub 2021 Jan 30.
本文引用的文献
1
Nicotinamide adenine dinucleotide-induced multimerization of the co-repressor CtBP1 relies on a switching tryptophan.
J Biol Chem. 2013 Sep 27;288(39):27836-48. doi: 10.1074/jbc.M113.493569. Epub 2013 Aug 12.
2
Molecular mechanism and functional role of brefeldin A-mediated ADP-ribosylation of CtBP1/BARS.
Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):9794-9. doi: 10.1073/pnas.1222413110. Epub 2013 May 28.
3
Genome-wide profiles of CtBP link metabolism with genome stability and epithelial reprogramming in breast cancer.
Nat Commun. 2013;4:1449. doi: 10.1038/ncomms2438.
4
Role of transcriptional corepressor CtBP1 in prostate cancer progression.
Neoplasia. 2012 Oct;14(10):905-14. doi: 10.1593/neo.121192.
5
C-terminal binding protein-2 regulates response of epithelial ovarian cancer cells to histone deacetylase inhibitors.
Oncogene. 2013 Aug 15;32(33):3896-903. doi: 10.1038/onc.2012.380. Epub 2012 Sep 3.
6
REFMAC5 for the refinement of macromolecular crystal structures.
Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):355-67. doi: 10.1107/S0907444911001314. Epub 2011 Mar 18.
7
Hallmarks of cancer: the next generation.
Cell. 2011 Mar 4;144(5):646-74. doi: 10.1016/j.cell.2011.02.013.
8
Expression of CtBP family protein isoforms in breast cancer and their role in chemoresistance.
Biol Cell. 2010 Jan;103(1):1-19. doi: 10.1042/BC20100067.
9
Therapeutic targeting of C-terminal binding protein in human cancer.
Cell Cycle. 2010 Sep 15;9(18):3740-50. doi: 10.4161/cc.9.18.12936. Epub 2010 Sep 8.
10
PHENIX: a comprehensive Python-based system for macromolecular structure solution.
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):213-21. doi: 10.1107/S0907444909052925. Epub 2010 Jan 22.
Zotero 插件